Why omega-3s keep showing up in child brain health studies
Omega-3 fatty acids—especially EPA and DHA—are structural and functional workhorses in the developing brain. Two new lines of research add nuance: one explores whether a mother’s omega-3 status during pregnancy relates to autism spectrum outcomes; the other tests if EPA supplements help children with ADHD—and for whom.
Maternal omega-3s and neurodevelopment: insights from MARBLES
What the study asked
The MARBLES project followed women who already had a child with autism and were planning another pregnancy, asking: Do omega-3 intakes and late-pregnancy blood levels relate to developmental outcomes (typical, non-typical, or ASD) in the next child?
How it was done
Researchers tracked 258 mother–child pairs. Omega-3 intake was estimated with food-frequency questionnaires in both halves of pregnancy, and third-trimester plasma was analyzed for EPA and DHA. Children received standardized developmental assessments at 36 months.
What stood out
-
Higher omega-3 intake in the second half of pregnancy was linked with a ~40% lower chance of an ASD diagnosis.
-
Higher late-pregnancy EPA and DHA in plasma correlated with a reduced risk of non-typical development (vs. typical), reinforcing earlier findings that better maternal omega-3 status supports healthier trajectories.
-
In this enriched-risk cohort, blood omega-3s tracked more strongly with non-typical outcomes than with ASD itself—useful, but not a blanket statement for the general population.
Why it matters
These results strengthen the idea that adequate maternal EPA/DHA during pregnancy may help lower the odds of atypical development—particularly in families already at higher risk. They also underscore timing: second-half intake and late-pregnancy blood status were most informative.
Omega-3s and ADHD: when personalization beats a one-size-fits-all dose
The key question
Do omega-3s improve ADHD symptoms—and for which children?
The trial in brief
In a randomized, placebo-controlled study of 92 children (6–18 years) with ADHD, participants received 1.2 g/day of EPA or placebo for 12 weeks. Researchers also measured baseline omega-3 status.
The nuance that changes practice
-
Children with low baseline EPA showed clear improvements in focused attention and vigilance on EPA—effect sizes (~0.8–0.9) that rival or exceed those typically seen with stimulants for these domains.
-
Children with normal/high EPA at baseline did not benefit; some showed worsened impulsivity on added EPA.
What this means clinically
This is personalized psychiatry in action: omega-3s can be potent when they correct a deficiency, not when layered on top of adequate levels. Before starting supplements, it’s sensible to consider dietary history, deficiency signs (e.g., very dry skin, eczema, dry eyes), and—ideally—a blood test.
Practical takeaways for families and clinicians
For pregnancy
-
Aim for steady DHA/EPA intake throughout pregnancy, with attention to the second half.
-
Low-mercury, DHA-rich seafood (salmon, sardines, herring) and/or a purified prenatal DHA can help reach adequate blood levels.
-
Because needs vary, consider measuring omega-3 status to guide dosing rather than guessing.
For ADHD
-
Omega-3s may meaningfully support attention and vigilance in children who are omega-3–deficient.
-
Benefits are not universal; adding high EPA to a child who already has good levels may be unhelpful or counterproductive.
-
Work with healthcare professionals; a targeted, status-informed approach is safer and more effective than blanket supplementation.
Bottom line
Omega-3s are not magic, but they’re also not marginal. The emerging theme is simple: measure, then match. In pregnancy, adequate maternal omega-3 status is a modifiable factor linked with healthier developmental outcomes. In ADHD, EPA can be a strong adjunct when it corrects a documented shortfall. As the science matures, personalization—not megadosing—looks like the smartest path forward.
